We use necessary cookies to make our website work. We'd also like to use optional cookies to understand how you use it, and to help us improve it.

For more information, please read our cookie policy.

Applicant should be assessed by Aeromedical Examiner (AME) for extent of psoriasis and assessed as unfit prior to initial dose of Ustekinumab. The assessment of fitness can be reviewed no sooner than 24 hours after the 2nd dose, which should be administered 4 weeks after the initial dose. The pilot or air traffic controller (ATCO) should be reviewed by their AME to assess the clinical response, ensure that there are no adverse effects and that residual psoriasis is unlikely to interfere with safety.

Unrestricted Class 1, 2, 3 or LAPL certification is possible.

Thereafter further doses will usually follow every 12 weeks and pilots/ATCOs should not fly or control for 24 hours after administration, to mitigate the risks of delayed hypersensitivity.

After a fit assessment, pilots/ATCOs should inform their AME of any adverse effects.

N.B. Pilots should not have live vaccines administered during treatment with Ustekinumab which may mean they are unable to travel to locations where live vaccines are recommended.